For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

Tissue biology research

ARA-290 10 mg Dosage Protocol

Evidence grade Human clinical trialBy Sam, MBALast reviewed October 2026

  • MW 1,257.3 g/mol
  • CAS 1208243-50-8
  • 10 mg

Vial sizes

Quick protocol card

ARA-290 10 mg · 4 mg daily for 28 days, subcutaneous, daily dose in the active arm[2] Human clinical trial

Unit Dose per draw4000 mcg (4 mg)
Vial
10 mg
Bacteriostatic water (mL)
2 mL
Concentration
5 mg/mL Calculated
Dose per draw
4,000 mcg (4 mg)[2]
Units on a U-100 syringe
80 units Calculated
Volume per draw
0.8 mL Calculated
Doses available from the vial
2 Calculated

Calculated from a default of 2 mL water (adjustable).

Source for the dose[2]

Dosage chart by source

Every range below is taken from the cited source and carries its evidence grade.

Human data and community reports

Human data and community reports
SourcePopulationDoseFrequencyRouteDurationEvidence
Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575)[2]human38 patients with sarcoidosis and small nerve fiber loss (21 ARA 290, 17 placebo)4 mg[2]subcutaneous, daily dose in the active armdaily for 28 dayssubcutaneous— Human clinical trialStudy details from the source: Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575): 38 sarcoidosis patients with small nerve fiber loss, 21 on ARA 290 4 mg subcutaneously daily for 28 days vs placebo; 4 mg chosen from a crossover pharmacokinetic study (2 mg IV, 2 mg SC, 4 mg SC, 6 mg)

Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.

Reconstitution

The figures follow the quick protocol card for this vial.

Calculated from a default of 2 mL water (adjustable).

  1. Wash your hands and wipe the vial stopper with an alcohol swab.
  2. Draw 2 mL of bacteriostatic water into a sterile syringe.
  3. Add the water slowly down the inside wall of the vial. Do not shake; swirl gently until the powder dissolves.
  4. The vial now holds 5 mg/mL. Label it with the date.
  5. For 4,000 mcg per draw[2], fill a U-100 syringe to 80 units.
0102030405060708090100

Supplies checklist

What to have ready before you reconstitute.

  • Bacteriostatic water (BAC water), USPUSP bacteriostatic water contains benzyl alcohol and is labelled only as a diluent; CDC: date a multiple-use vial and discard it within 28 days. Source: labeling.pfizer.com
  • U-100 insulin syringe, 1 mL (100 units)Standard U-100 insulin syringes hold 1 mL (100 units); each small notch on a 1 mL syringe is 1 unit. Source: medlineplus.gov
  • Alcohol prep pads (isopropyl)CDC lists alcohol wipes among supplies for the medication preparation area; MedlinePlus: wipe the vial top with an alcohol wipe. Source: cdc.gov
  • FDA-cleared sharps disposal containerFDA recommends used needles and sharps go immediately into an FDA-cleared sharps disposal container, made of rigid plastic with a fill line. Source: fda.gov

All supplies and why each is needed

Side effects, contraindications and regulatory status

Reported side effects

  • Trial in sarcoidosis small-fiber neuropathy (38 patients; 21 on ARA 290 4 mg subcutaneously daily for 28 days): no serious adverse events during dosing or 12 weeks of follow-up; no pain or local irritation at the injection site.[2] Human trial
  • Same trial: one ARA 290 patient had a moderate adverse event of 14 kg weight loss that, per the paper, began before study entry and persisted after dosing stopped; no anti-ARA 290 antibodies were detected in the post-dose samples tested.[2] Human trial
  • Registry results, daily subcutaneous dosing for 28 days: serious adverse events in 2 of 16 (1 mg), 0 of 16 (4 mg), 1 of 14 (8 mg; suicidal ideation) and 0 of 16 (placebo) participants; headache, nausea and diarrhea were among other events listed.[1] Human trial

Cautions from reviews and trials

  • Trial exclusion (registry NCT02039687): pregnancy or breast-feeding; use of erythropoiesis-stimulating agents within two months before screening or during the trial; serious malignancy within the last 5 years (other than removed skin carcinoma).[1] Human trial

Regulatory status

Investigational: phase 2 registry record NCT02039687 (completed 2015-02); the record lists no approval. Not on the FDA bulk-substance safety-risk page (2026-04-22). Checked 2026-10-20.[1] Source

Report any adverse reaction to a qualified healthcare professional.

What the research says

Summaries of the cited studies, each with its evidence grade.

  • Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575)[2]

    Human trial human

    Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575): 38 sarcoidosis patients with small nerve fiber loss, 21 on ARA 290 4 mg subcutaneously daily for 28 days vs placebo; 4 mg chosen from a crossover pharmacokinetic study (2 mg IV, 2 mg SC, 4 mg SC, 6 mg)

    Human clinical trial

  • ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled)[1]

    Human trial human

    ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled): daily subcutaneous ARA 290 at 1, 4 or 8 mg or placebo for 28 days, 12-week follow-up; self-injected at home after the first dose at the site

    Human clinical trial

Compare vial sizes

Compare vial sizes
SizePriceDoses available from the vial CalculatedCost per dose Calculated
10 mg This page$64.992$32.50

Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.

Calculated from a default of 2 mL water (adjustable).

Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.

Frequently asked questions

What is ARA-290?

ARA-290 (also listed as Cibinetide, ARA 290) is listed on this site under Tissue biology research. This page collects what published sources report about it: cited figures with evidence grades, vial sizes, storage and its regulatory status. Identity data such as the CAS number, molecular weight and sequence are shown with their source in the identity section.

What dose figures are published for ARA-290?

Cited figures on this page: 4 mg daily for 28 days, subcutaneous, daily dose in the active arm [2] (Human clinical trial, evidence grade B). These are summaries of published sources, not medical advice. Each figure links to its source in the references.

How many doses are in a 10 mg vial of ARA-290?

At 4 mg daily for 28 days, subcutaneous, daily dose in the active arm [2] (the cited dose and frequency), a 10 mg vial reconstituted with 2 mL of water (5 mg/mL) provides about 2 doses, each 80 units on a U-100 syringe. Calculated from a default of 2 mL water (adjustable); only the dose and frequency are cited.

What is the regulatory status of ARA-290?

Investigational: phase 2 registry record NCT02039687 (completed 2015-02); the record lists no approval. Not on the FDA bulk-substance safety-risk page (2026-04-22). Checked 2026-10-20.

References

Numbered sources used on this page. Markers in the text link here.

  1. ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled) clinicaltrials.gov Human trial
  2. Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575) pmc.ncbi.nlm.nih.gov Human trial

Available from Pepcore

Supplied as research material for laboratory use only.

  • ARA-290 Research Material - 10mg 10 mg$64.99
    Shop at PepcoreCoupon code LAUNCH20

Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.